<u>Unite</u>	ED STATES PATENT 2	and Trademark Office	UNITED STATES DEPARTM United States Patent and T Address: COMMISSIONER OF P/ Washington, D.C. 20231 www.uspto.gov	ademark Office	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/916,440	07/30/2001	Jing Wu	002010-586	2003	
21839 7590 04/05/2002 BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			EXAMINER		
			KIFLE, BRUCK		
			ART UNIT	PAPER NUMBER	
			1624 DATE MAILED: 04/05/2002	7	

١

Please find below and/or attached an Office communication concerning this application or proceeding.

÷-

с								
Office Action Symmony	Application No. 09/916,440	Applicant(s)	Applicant(s) Wu et al.					
Office Action Summary	Examiner Bruck Kifle, Ph.D.		Art Unit 1624					
The MAILING DATE of this communication app	pears on the cover sheet w	vith the corres	pondence addr	ess				
 Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this come If the period for reply specified above is less than thirty (30) be considered timely. If NO period for reply is specified above, the maximum state communication. Failure to reply within the set or extended period for reply we Any reply received by the Office later than three months aft earned patent term adjustment. See 37 CFR 1.704(b). 	37 CFR 1.136 (a). In no even munication. days, a reply within the sta utory period will apply and w vill, by statute, cause the app	ent, however, t tutory minimun ill expire SIX (f plication to bec	may a reply be ti n of thirty (30) d 3) MONTHS from ome ABANDONE	ays will 1 the mailing date of this ED (35 U.S.C. § 133).				
Status Status 1) X Responsive to communication(s) filed on <u>Mar</u>	18, 2002							
2a) 🗌 This action is FINAL. 2b) 🔀 Thi	is action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.								
Disposition of Claims								
4) 💢 Claim(s) <u>91-145</u>	is/are	e pending in th	e application.					
4a) Of the above, claim(s) <u>96-103, 105-108, 12</u>	23-130, and 132-135	is/ar	e withdrawn f	rom consideration.				
5) 🗌 Claim(s)		is/are allowed						
6) 🔀 Claim(s) <u>91-95, 104, 109-122, 131, and 136-</u>		is/are rejected	I.					
7) 🗌 Claim(s)		is/are objected to.						
8) 🗌 Claims	are sub	ject to restric	ction and/or ele	ection requirement.				
Application Papers 9) The specification is objected to by the Examin								
10) The drawing(s) filed on i								
11) The proposed drawing correction filed on		approved	b) 🗀 disappro	ved.				
12) \Box The oath or declaration is objected to by the E	xaminer.							
Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for fore a) All b) Some* c) None of:	ign priority under 35 U.S	S.C. § 119(a)	-(d).					
1. Certified copies of the priority documents have been received.								
2. \Box Certified copies of the priority documents	2. \Box Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the prior application from the International *See the attached detailed Office action for a list	Bureau (PCT Rule 17.2(a)).	this National	Stage				
14) \mathbf{X} Acknowledgement is made of a claim for dom			e).					
Attachment(s)								
15) Notice of References Cited (PTO-892)	18) 🔲 Interview Summary	/ (PTO-413) Paper	No(s).					
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal							
17) X Information Disclosure Statement(s) (PTO-1449) Paper No(s).1 and	4 20) 🗌 Other:							


. •

Art Unit: 1624


.

Election/Restriction

Applicant's election without traverse of the compound depicted below in Paper No. 6 is acknowledged.



The search was conducted to embrace compounds wherein W, together with - $C(H)_{p}C(=X)$, and Q form the ring system:



Claims 96-103, 105-108, 123-130 and 132-135 along with subject matter not embraced by this ring system of the remaining claims are withdrawn from consideration as being drawn to non-elected subject matter.

Improper Markush Rejection

Claims 91-95, 104, 109-122, 131 and 136-145 are rejected under a judicially created doctrine as being drawn to an improper Markush group, that is, the claims lack unity of invention. The ring formed by W, together with $-C(H)_pC(=X)$, and Q are defined in such a way

Art Unit: 1624

that they keep changing the core of the compound that determines the classification. By changing these values, several patentably distinct and independent compounds are claimed. In order to have unity of invention the compounds must have "a community of chemical or physical characteristics" which justify their inclusion in a common group, and that such inclusion is not repugnant to principles of scientific classification" In re JONES (CCPA) 74 USPQ 149 (see footnote 2). The structural formula IA and IB do not have a significant structural feature that is shared by all of its alternatives which is inventive. The structural formula IA and IB only have the -C(O)-NH-CH(R²)-C(O)-NH- fragment as common. Compounds embraced by formula IA and IB are so diverse in nature that a prior art anticipating a claim with respect to one member under 35 USC 102 would not render obvious the same claim under 35 USC 103. This is evidentiary of patentably distinct and independent inventions.

Limiting the claims to compounds wherein W, together with $-C(H)_pC(=X)$, and Q form the elected ring system (the benzoazepinone ring) would overcome this rejection.

Claim Rejections - 35 USC § 112

Claims 91-95, 104, 109-122, 131 and 136-145 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

i) In the independent claims the terms substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkenyl are present. The term "substituted" without saying which substituents

Art Unit: 1624

•

are intended is indefinite. One skilled in the art cannot say which substituents are permitted and which ones are not.

ii) The term "cycloalkyl" is indefinite because it is not known how many atoms make up the ring and what kind of a ring is intended (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.).iii) The term "heteroaryl" is indefinite because it is not known how many atoms are present, how many and what kind of heteroatoms are involved, what size ring is intended and how many rings are present.

iv) The term "heterocyclic" is indefinite because it is not known how many atoms make up the ring, which atoms are present and what kind of a ring (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.) is intended.

v) The independent claims end with the phrase "and pharmaceutically acceptable salts thereof." This is improper Markush language because it is not in the alternative form. The term "or" is suggested in place of "and".

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely

.41

exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, the independent claims recite the broad recitations "optionally substituted heteroaryl" and "substituted alkyl", and the claims also recite "2-aminopyrid-6-yl" and "-(CH₂)₄NHC(O)OC(CH₃)₃" which is the narrower statement of the range/limitation.

Applicants are reminded that although the claims are interpreted in light of the specification, critical limitations from the specification cannot be read into the claims (see, e.g., In re Van Guens, 988 F.2d 1181, 26 PSPG2d 1057 (Ded. Cir. 1991)). Accordingly, without the recitation of all these critical limitations, the claims do not adequately define the instant invention.

Claim 145 has 68 pages of compounds. This number of compounds cannot be considered "a reasonable number" according to rule 1.140(a). See also MPEP rule 1.141(a) reproduced below.

§ 1.141 Different inventions in one national application.

(a) Two or more independent and distinct inventions may not be claimed in one national application, except that more than one species of an invention, not to exceed a reasonable number, may be specifically claimed in different claims in one national application, provided the application also includes an allowable claim generic to all the claimed species and all the claims to species in excess of one are written in dependent form (1.75) or otherwise include all the limitations of the generic claim.

Art Unit: 1624

Provisos

There are provisos in the claims that exclude compounds embraced by the claims. If these provisos are present to avoid prior art, applicants are urgently requested to point out these references to the examiner because of their importance in the examination of the claims.

The search revealed that the elected compound is disclosed in several of Applicants pending applications. See for example WO 9/67221 and WO 98/28268. Also, WO 2001/034571 overlaps generically. Applicants are required to maintain a clear line of demarcation between the applications. See MPEP § 822.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

April 4, 2002

Sunde X/4

Bruck Kifle[®] Primary Examiner Art Unit 1624